Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells

被引:151
|
作者
Zhao, Yunlong [1 ]
Harrison, Devin L. [2 ]
Song, Yuran [1 ]
Ji, Jie [2 ,3 ]
Huang, Jun [2 ]
Hui, Enfu [1 ]
机构
[1] Univ Calif San Diego, Div Biol Sci, Sect Cell & Dev Biol, La Jolla, CA 92093 USA
[2] Univ Chicago, Inst Mol Engn, Chicago, IL 60637 USA
[3] Nanjing Med Univ, Clin Med Coll 1, Dept Hepatobiliary Surg, Nanjing 210029, Jiangsu, Peoples R China
来源
CELL REPORTS | 2018年 / 24卷 / 02期
基金
美国国家科学基金会;
关键词
COSTIMULATORY RECEPTOR; CANCER-IMMUNOTHERAPY; B7; FAMILY; EXPRESSION; ACTIVATION; EXHAUSTION; SECRETION; BIOMARKER; BILAYERS; SURVIVAL;
D O I
10.1016/j.celrep.2018.06.054
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The PD-1 pathway, consisting of the co-inhibitory receptor PD-1 on T cells and its ligand (PD-L1) on antigen- presenting cells (APCs), is a major mechanism of tumor immune evasion. PD-1 and PD-L1 blockade antibodies have produced remarkable clinical activities against a subset of cancers. Binding between T cell-intrinsic PD-1 and APC-intrinsic PD-L1 triggers inhibitory signaling to attenuate the T cell response. Here, we report that PD-1 is co-expressed with PD-L1 on tumor cells and tumor-infiltrating APCs. Using reconstitution and cell culture assays, we demonstrate that the co-expressed PD-1 binds to PD-L1 in cis. Such interaction inhibits the ability of PD-L1 to bind T cell-intrinsic PD-1 in trans and, in turn, represses canonical PD-L1/PD-1 inhibitory signaling. Selective blockade of tumor-intrinsic PD-1 frees up tumor-intrinsic PD-L1 to inhibit T cell signaling and cytotoxicity. Our study uncovers another dimension of PD-1 regulation, with important therapeutic implications.
引用
收藏
页码:379 / +
页数:18
相关论文
共 50 条
  • [41] PD-1 AND PD-L1 EXPRESSION IN OVARIAN CANCER
    Wieser, V.
    Gaugg, I.
    Fleischer, M.
    Fiegl, H.
    Marth, C.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 64 - 64
  • [42] PD-L1/PD-1 Axis in Glioblastoma Multiforme
    Litak, Jakub
    Mazurek, Marek
    Grochowski, Cezary
    Kamieniak, Piotr
    Rolinski, Jacek
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (21)
  • [44] PD-1 and PD-L1 expression in cardiac transplantation
    Bishawi, Muath
    Bowles, Dawn
    Pla, Michelle Mendiola
    Oakes, Faye
    Chiang, Yuting
    Schroder, Jacob
    Milano, Carmelo
    Glass, Carolyn
    CARDIOVASCULAR PATHOLOGY, 2021, 54
  • [45] New Era Beyond PD-1/PD-L1
    Paz-Ares, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S127 - S127
  • [46] PD-1/PD-L1 Pathway in Breast Cancer
    Schuetz, Florian
    Stefanovic, Stefan
    Mayer, Luisa
    von Au, Alexandra
    Domschke, Christoph
    Sohn, Christof
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (05) : 294 - 297
  • [47] PD-1/PD-L1 and immunotherapy for pancreatic cancer
    Feng, Mengyu
    Xiong, Guangbing
    Cao, Zhe
    Yang, Gang
    Zheng, Suli
    Song, Xujun
    You, Lei
    Zheng, Lianfang
    Zhang, Taiping
    Zhao, Yupei
    CANCER LETTERS, 2017, 407 : 57 - 65
  • [48] PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis
    Carter, Laura L.
    Leach, Michael W.
    Azoitei, Mihai L.
    Cui, Junqing
    Pelker, Jeffrey W.
    Jussif, Jason
    Benoit, Steve
    Ireland, Gretchen
    Luxenberg, Deborah
    Askew, G. Roger
    Milarski, Kim L.
    Groves, Christopher
    Brown, Tom
    Carito, Brenda A.
    Percival, Karen
    Carreno, Beatriz M.
    Collins, Mary
    Marusic, Suzana
    JOURNAL OF NEUROIMMUNOLOGY, 2007, 182 (1-2) : 124 - 134
  • [49] Antagonists of PD-1 and PD-L1 in Cancer Treatment
    Lipson, Evan J.
    Forde, Patrick M.
    Hammers, Hans-Berg
    Emens, Leisha A.
    Taube, Janis M.
    Topalian, Suzanne L.
    SEMINARS IN ONCOLOGY, 2015, 42 (04) : 587 - 600
  • [50] PD-1/PD-L1 axis in organ fibrosis
    Zhao, Youliang
    Qu, Yaqian
    Hao, Changfu
    Yao, Wu
    FRONTIERS IN IMMUNOLOGY, 2023, 14